Leptin mediates the lipopolysaccharide-increased pulmonary permeability in rats
October 19, 2010
Leptin mediates the lipopolysaccharide-increased pulmonary permeability in rats
This is an automatically generated default intro template – please do not edit.
General information |
|
Title: | Leptin mediates the lipopolysaccharide-increased pulmonary permeability in rats |
Meta keywords: | |
Meta description: | |
Images information |
|
Images path absolute: | |
Images path relative: | |
Thumbs path absolute: | |
Thumbs path relative: | |
Fields information |
|
Article_Title: | Leptin mediates the lipopolysaccharide-increased pulmonary permeability in rats |
Authors: | Bogdan Cristian Petrescu, Bogdan Gurzu, Roxana Irina Iancu, Anca Indrei, Irina Luciana Dumitriu, Liliana Chelaru, Simona Mihaela Slatineanu, Gheorghe Petrescu, Marcel Costuleanu |
Affiliation: | University of Medicine and Pharmacy “Gr. T. Popa” Iasi, Romania |
Abstract: | The aim of our study was represented by the leptin involvement as a mediator of lipopolysaccharide (LPS)-increased pulmonary permeability in rats. Pretreatment with aminoguanidine (20 mg/kg i.p), 2-aminopurine (20 mg/kg i.p.) and subjecting to food deprivation (48 h, with water ad libitum) reduced the LPS-induced vascular leak, measured as Evans blue extravasation in lung tissue, by 41.70%, 21.39% and, respectively, 52.92%, when compared to LPS (10µg/kg, 100µl aliquots) administered alone. In addition, leptin alone induced Evans blue leakage that represents 74.38% from that induced by LPS. Since the inhibitory effects of 2-aminopurine are with 59.34% higher than that induced by aminoguanidine on leptin, we were able to conclude that leptin is at least partially mediating the LPS-increased pulmonary permeability in rats. Lung concentrations of leptin might increase as an early event of LPS challenge. Furthermore, leptin effects might be partially realized through NO production after leptin receptors activation. |
Keywords: | leptin, lipopolysaccharide, nitric oxide, pulmonary permeability, rat |
References: | Allman M, Wallace M, Gaskin L, Rivera CA, Leptin induces an inflammatory phenotype in lean wistar rats. Mediators Inflamm, 2009:738620. Epub 2010. Andrews AM, Armstrong AD, Marshall I, Malur A, Mccoy AJ, Thomassen MJ, PPAR-γ and leptin in pulmonary inflammation. Ethn Dis, 19(2), S1-S2, suppl. 3, 2009. Fernández-Riejos P, Najib S, Santos-Alvarez J, Martín-Romero C, Pérez-Pérez A, González-Yanes C, Sánchez-Margalet V, Role of leptin in the activation of immune cells. Mediators Inflamm, 2010:568343. Epub 2010. Hosoi T, Matsunami N, Nagahama T, Okuma Y, Ozawa K, Takizawa T, Nomura Y, 2-Aminopurine inhibits leptin receptor signal transduction. Eur J Pharmacol, 28, 553(1-3), 61-66, 2006. Mancuso P, Obesity and lung inflammation. J Appl Physiol, 108(3), 722-728, 2010. Matarese G, Mantzoros C, La Cava A, Leptin and adipocytokines: bridging the gap between immunity and atherosclerosis. Curr Pharm Des, 13(36), 3676-3680, 2007. McIntyre RC, Pulido EJ, Bensard DD, Shames BD, Abraham E, Thirty years of clinical trials in acute respiratory distress syndrome. Crit Care Med, 28, 3314-3331, 2000. Merry HE, Wolf PS, Fitzsullivan E, Keech JC, Mulligan MS, Lipopolysaccharide pre-conditioning is protective in lung ischemia-reperfusion injury. J Heart Lung Transplant, 29(4), 471-478, 2010. Rummel C, Inoue W, Poole S, Luheshi GN, Leptin regulates leukocyte recruitment into the brain following systemic LPS-induced inflammation. Mol Psychiatry, 15(5), 523-534, 2010. Sood A, Obesity, adipokines, and lung disease. J Appl Physiol, 108(3), 744-753, 2010. Sugiyama T, Fujita M, Koide N, Mori I, Yoshida T, Mori H, Yokochi T, 2-Aminopurine inhibits lipopolysaccharide-induced nitric oxide production by preventing IFN-beta production. Microbiol Immunol, 48(12), 957-963, 2004. Tulić MK, Wale JL, Holt PG, Sly PD, Differential effects of nitric oxide synthase inhibitors in an in vivo allergic rat model. Eur Respir J, 15(5), 870-877, 2000. |
Read_full_article: | pdf/20-2010/20-2-2010/SU20-2-10Petrescu.pdf |
Correspondence: | Marcel Costuleanu, University of Medicine and Pharmacy “Gr. T. Popa” Iasi, Faculty of Dental Medicine, Department of General and Oro-Maxillo-Facial Pathology, 16, University Str., 700115, Iasi, Romania, Tel. +40-745-589050, Fax. +40-232-211820, email: mcostuleanu@yahoo.com |
Read full article | |
Article Title: | Leptin mediates the lipopolysaccharide-increased pulmonary permeability in rats |
Authors: | Bogdan Cristian Petrescu, Bogdan Gurzu, Roxana Irina Iancu, Anca Indrei, Irina Luciana Dumitriu, Liliana Chelaru, Simona Mihaela Slatineanu, Gheorghe Petrescu, Marcel Costuleanu |
Affiliation: | University of Medicine and Pharmacy “Gr. T. Popa” Iasi, Romania |
Abstract: | The aim of our study was represented by the leptin involvement as a mediator of lipopolysaccharide (LPS)-increased pulmonary permeability in rats. Pretreatment with aminoguanidine (20 mg/kg i.p), 2-aminopurine (20 mg/kg i.p.) and subjecting to food deprivation (48 h, with water ad libitum) reduced the LPS-induced vascular leak, measured as Evans blue extravasation in lung tissue, by 41.70%, 21.39% and, respectively, 52.92%, when compared to LPS (10µg/kg, 100µl aliquots) administered alone. In addition, leptin alone induced Evans blue leakage that represents 74.38% from that induced by LPS. Since the inhibitory effects of 2-aminopurine are with 59.34% higher than that induced by aminoguanidine on leptin, we were able to conclude that leptin is at least partially mediating the LPS-increased pulmonary permeability in rats. Lung concentrations of leptin might increase as an early event of LPS challenge. Furthermore, leptin effects might be partially realized through NO production after leptin receptors activation. |
Keywords: | leptin, lipopolysaccharide, nitric oxide, pulmonary permeability, rat |
References: | Allman M, Wallace M, Gaskin L, Rivera CA, Leptin induces an inflammatory phenotype in lean wistar rats. Mediators Inflamm, 2009:738620. Epub 2010. Andrews AM, Armstrong AD, Marshall I, Malur A, Mccoy AJ, Thomassen MJ, PPAR-γ and leptin in pulmonary inflammation. Ethn Dis, 19(2), S1-S2, suppl. 3, 2009. Fernández-Riejos P, Najib S, Santos-Alvarez J, Martín-Romero C, Pérez-Pérez A, González-Yanes C, Sánchez-Margalet V, Role of leptin in the activation of immune cells. Mediators Inflamm, 2010:568343. Epub 2010. Hosoi T, Matsunami N, Nagahama T, Okuma Y, Ozawa K, Takizawa T, Nomura Y, 2-Aminopurine inhibits leptin receptor signal transduction. Eur J Pharmacol, 28, 553(1-3), 61-66, 2006. Mancuso P, Obesity and lung inflammation. J Appl Physiol, 108(3), 722-728, 2010. Matarese G, Mantzoros C, La Cava A, Leptin and adipocytokines: bridging the gap between immunity and atherosclerosis. Curr Pharm Des, 13(36), 3676-3680, 2007. McIntyre RC, Pulido EJ, Bensard DD, Shames BD, Abraham E, Thirty years of clinical trials in acute respiratory distress syndrome. Crit Care Med, 28, 3314-3331, 2000. Merry HE, Wolf PS, Fitzsullivan E, Keech JC, Mulligan MS, Lipopolysaccharide pre-conditioning is protective in lung ischemia-reperfusion injury. J Heart Lung Transplant, 29(4), 471-478, 2010. Rummel C, Inoue W, Poole S, Luheshi GN, Leptin regulates leukocyte recruitment into the brain following systemic LPS-induced inflammation. Mol Psychiatry, 15(5), 523-534, 2010. Sood A, Obesity, adipokines, and lung disease. J Appl Physiol, 108(3), 744-753, 2010. Sugiyama T, Fujita M, Koide N, Mori I, Yoshida T, Mori H, Yokochi T, 2-Aminopurine inhibits lipopolysaccharide-induced nitric oxide production by preventing IFN-beta production. Microbiol Immunol, 48(12), 957-963, 2004. Tulić MK, Wale JL, Holt PG, Sly PD, Differential effects of nitric oxide synthase inhibitors in an in vivo allergic rat model. Eur Respir J, 15(5), 870-877, 2000. |
*Correspondence: | Marcel Costuleanu, University of Medicine and Pharmacy “Gr. T. Popa” Iasi, Faculty of Dental Medicine, Department of General and Oro-Maxillo-Facial Pathology, 16, University Str., 700115, Iasi, Romania, Tel. +40-745-589050, Fax. +40-232-211820, email: mcostuleanu@yahoo.com |